About DNA nucleotidylexotransferase
DNA nucleotidylexotransferase (DNTT) is a protein
from Homo sapiens identified by UniProt accession
P04053, 509 residues long.
MolForge cross-references it against 0 known binders and
318 disease associations.
Target properties
| Protein name | DNA nucleotidylexotransferase |
| UniProt accession | P04053 |
| Gene | DNTT |
| Organism | Homo sapiens |
| Length | 509 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (318)
Diseases linked to this target (Open Targets).
- acute lymphoblastic leukemia · score 0.09
- experimental autoimmune encephalomyelitis · score 0.08
- neoplasm · score 0.07
- infection · score 0.07
- infect · score 0.07
- Okt4 epitope deficiency · score 0.06
- Thymoma · score 0.06
- acute myeloid leukemia · score 0.05
- hypertriglyceridemia 2 · score 0.05
- cholesterol-ester transfer protein deficiency · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P04053-F1 | alphafold | PREDICTED | 88.03 | — |
Amino-acid sequence (509 residues)
MDPPRASHLS PRKKRPRQTG ALMASSPQDI KFQDLVVFIL EKKMGTTRRA FLMELARRKG FRVENELSDS VTHIVAENNS GSDVLEWLQA QKVQVSSQPE LLDVSWLIEC IRAGKPVEMT GKHQLVVRRD YSDSTNPGPP KTPPIAVQKI SQYACQRRTT LNNCNQIFTD AFDILAENCE FRENEDSCVT FMRAASVLKS LPFTIISMKD TEGIPCLGSK VKGIIEEIIE DGESSEVKAV LNDERYQSFK LFTSVFGVGL KTSEKWFRMG FRTLSKVRSD KSLKFTRMQK AGFLYYEDLV SCVTRAEAEA VSVLVKEAVW AFLPDAFVTM TGGFRRGKKM GHDVDFLITS PGSTEDEEQL LQKVMNLWEK KGLLLYYDLV ESTFEKLRLP SRKVDALDHF QKCFLIFKLP RQRVDSDQSS WQEGKTWKAI RVDLVLCPYE RRAFALLGWT GSRQFERDLR RYATHERKMI LDNHALYDKT KRIFLKAESE EEIFAHLGLD YIEPWERNA
Explore DNA nucleotidylexotransferase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets